News

LMW stock price revised July 1, 2010

 The Board of Directors has approved a revision of the stock value of LMW Inc. to a value of $5258 / share effective July 1, 2010. This value continues to be based on a "snapshot" of all current assets. This represents a 42.7% increase in stock value in the past 12 month period.

"We have exceeded our targets consistently in 2010 and are poised for even greater share value as the year progresses. As we transition to GAP accounting standards we are finding our strategies sound, and our fiscal discipline and delivery model returning solid profits. " L. Westby, President.

LMW Inc. is a privately held corporation with no stock for sale. 

NIH Project Expands

 After reviewing preliminary patient volumes, and outcome information the National Institute of Health has moved from the pilot phase of the project into a full Phase I implementation.  This will allow a regional roll out of new centers based within community health centers and hospital outreach projects. Organizations will apply directly to NIH to become candidates, and LMW will further screen candidates for priority of placement.

"Our ability to "connect" with our patients and move them quickly through the diagnostic testing to an initial treatment plan continues to be a strong care model" stated Larry Westby, President " We look forward to working with proactive physicians and organizations to continue to expand care for asthma patients and their families".

Phase I will allow for a 600 center project at full capacity. 

LMW Inc. Announces Price Revision

 The Board of Directors has approved a revision of the LMW Inc. stock price to $4321.00 a share of common stock effective April 1, 2010. The methodology was unchanged from last years increase to provide a "snapshot" of current assets, not utilizing forward looking statements or projections in this formula.

This represents a monthly rate of increase 2.6 times over the 2009 earnings. The company is accruing value at a rate of 152.63 a month per common share resulting in a $1221.00 per share increase in an 8 month period.

"We have maintained our philosophy of investing in our key components, resulting in a wide range of applications for our providers. This is now returning value to the company as demand for our services increases" remarked Larry Westby, President  "We will begin to calculate and report share value on a schedule of 2-3x a year as we have reduced episodic variables, and move towards our goal of testing the acquisition market later this year". I encourage our shareholders to review our Annual Report scheduled for release in April for further information.

LMW Inc. is a privately owned company with no additional stock for sale. 

Tom Petty M.D.

 It is with great sadness that we recognize the passing of one of the pioneering pulmonary physicians, and one of our friends, Thomas Petty MD. Dr Petty passed away over the holidays after a long illness.

Tom inspired many who worked with chronic pulmonary disease patients, and was instrumental in the development of many of the guidelines our company uses with COPD patients. I know he enjoyed our success in establishing NLHEP based clinics, and the numbers of patients / physicians we assist with the early utilization of spirometry.

He will be missed by the profession, and by us at LMW Inc. He leaves a lasting legacy.

Board of Directors Approves 2nd 09 Dividend

The Board of Directors has approved a second dividend of $13.00 / share which will be distributed December 1, 2009.

"As indicated with our spring dividend, we chose to move further into the years operation and then reassess our ability to add to the stockholder dividend for the year. We have had continued success moving forward, which allows us to provide a second dividend for our shareholders" Stated Larry Westby, President. "While we have had some challanges, we are confident that this distribution will not adversely affect any of our plans."

There will be a distribution detail listed within the investor section as the date approaches.

LMW Inc announces Stock Price Revision

 The LMW Inc. Board of Directors has reviewed and approved a revision to the stock price of LMW Inc.

The stock price, effective August 1, 2009 will move to $3100.00 a share of common stock. This represents an increase of $700.00 a share in the past year. A formula was utilized that provides a "snapshot" of the companies economic assets in 2009. The decision was made not to utilize forward looking statements or projections in this formula. 

"The continued rise in the stock price represents our commitment to use our resources to meet our stated 2009 goal of maximizing our company value, which is reflected in the new stock price. The value of each share of stock has grown by $58.30 a month over the past year. We are proud of this accomplishment in what can only be described as a challenging economic environment." Stated Larry Westby, President

LMW Inc is a privately owned company which has no additional stock for sale.

LMW Inc presents data to NIH Committee

A team from LMW Inc. presented program data at a 2 day Meeting with the National Instiute of Health in Washington DC. The Committee was comprised of NIH and Health & Human Services members evaluating "Programs that Work" to help meet the goals in new health care reform.

After a full day of presentations and discussions, day two was spent evaluating the impact our programs could have in asthmacare nationally. We have agreed to jointly develop a demonstration "pilot" project, which would be provided at NIH designated locations to evaluate our effectiveness with specific populations.

"As a provider, it is important to be proactively involved with any goverment health care reform" stated Larry Westby "We welcome the challange of providing quality care to medically underserved populations and feel this will allow us to evaluate the costs associated with regional or national programs."

We anticipate a 90 days joint development period prior to center start ups. More to follow on this project as we move forward.

Board of Directors Approves Dividend

 The Board of Directors have authorized a dividend of $7.00 / share to be paid May 1, 2009.

"Our discussions revolved around the need to hold cash for operations in a very challenging environment" stated Larry Westby, president "We reserve the right to revisit the issue in the fall, based on continued success in this economy".

"Further information will follow in our annual report, however we wanted to get money back into the hands of our investors, as we have it available outside of our operational needs. We will need to maintain an increased operational reserve, to provide us flexibility moving forward. Very few companies are able to provide investors a return at this time, but we are all in agreement that we remain committed to returning dollars to investors which do not put us at risk."

"I want to stress that we are feeling the strains of the current economy with an extended AR, and the transition from building centers, to operating them profitably until the acquisition market is revitalized. We are, to a degree reaping the benefits of having rapidly built our network in the past 3 year period."said Westby " that growth would not be possible today.  Our emphasis now shifts from growth to profitable operations"

In other news; the Board appreciated the efforts which resulted in the on time /  on budget relaunch of our web site, and approved the mid / late March release of the 2008 Annual Report.

Asthma Program Wins National Recognition

The Center For Pharmeceutical Economics has recognized the LMW Inc asthma treatment program  as a 'Program That Works" for 2008.  This was based on analysis of outcome data from 600 patients with moderate persistant asthma treated in the primary physician office utilizing the LMW Inc treatment model.

"This program reduced total cost of care by changing the management site from the acute care hospital / ER setting to the lower cost physician office setting". Stated J. Brandman, research fellow " We also saw decreased variation in asthma treatment and increased patient adherance to their individualized treatment plan".

This information will be jointly presented to the National Institute of Health; Heart, Lung, Blood Institute in 2009. "We will be there to further explain our program, and discuss our ability to further impact the problem nationally" Stated Larry Westby  president of LMW Inc.